
Jeplus.in
Purchase All Medicines.Get 10% Offer

PharmaShots
Shots: Eli Lilly has entered into a definitive agreement to acquire Calytrix Bio; Calytrix shareholders could receive up to $1.5B in cash, incl. an upfront payment & subsequent clinical & regulatory milestones The acquisition adds Calytrix’s lead preclinical biparatopic antibody, which targets both Type 1 & Type 2 mutant calreticulin (mCALR) for mCALR-driven essential thrombocythemia… The post Eli Lilly to Acquire Calytrix Bio for Up to $1.5B to Expand its Blood Cancer Pipeline appeared first on PharmaShots.

Pharma Tech
The deal sees J&J bolster its pipeline with a bispecific antibody in Phase III development for wAMD and DME.

PharmaShots
Shots: Johnson & Johnson has entered into a definitive agreement to acquire Ollin Biosciences for $2.2B upfront, with potential regulatory & commercial milestones of up to ~$1.125B; closing is expected before the end of 2026 The acquisition adds OLN324, a P-III VEGF/Ang2 bispecific antibody with high Ang2 potency & a small minibody format, being developed… The post Johnson & Johnson to Acquire Ollin Biosciences for ~$3.3B to Expand its Ophthalmology Pipeline appeared first on PharmaShots.

Pharma Tech
One of oncology’s biggest success stories this year, RevMed's Rasonque, has started with strong uptake in the US.

Pharma Tech
Flagship's UK investment marks another sign of turning tides for the UK life sciences sector, following prior big pharma funding pullouts.
Sponsored content

Purchase All Medicines.Get 10% Offer
News
PharmaShots
Nov 16, 2026, 11:25 PM
Shots: Eli Lilly has entered into a definitive agreement to acquire Calytrix Bio; Calytrix shareholders could receive up to $1.5B in cash, incl. an upfront payment & subsequent clinical & regulatory milestones The acquisition adds Calytrix’s lead preclinical biparatopic antibody, which targets both Type 1 & Type 2 mutant calreticulin (mCALR) for mCALR-driven essential thrombocythemia… The post Eli Lilly to Acquire Calytrix Bio for Up to $1.5B to Expand its Blood Cancer Pipeline appeared first on PharmaShots.
Pharma Tech
Nov 16, 2026, 5:03 PM
The deal sees J&J bolster its pipeline with a bispecific antibody in Phase III development for wAMD and DME.
PharmaShots
Nov 16, 2026, 4:47 PM
Shots: Johnson & Johnson has entered into a definitive agreement to acquire Ollin Biosciences for $2.2B upfront, with potential regulatory & commercial milestones of up to ~$1.125B; closing is expected before the end of 2026 The acquisition adds OLN324, a P-III VEGF/Ang2 bispecific antibody with high Ang2 potency & a small minibody format, being developed… The post Johnson & Johnson to Acquire Ollin Biosciences for ~$3.3B to Expand its Ophthalmology Pipeline appeared first on PharmaShots.
Pharma Tech
Nov 16, 2026, 4:15 PM
One of oncology’s biggest success stories this year, RevMed's Rasonque, has started with strong uptake in the US.
Pharma Tech
Nov 16, 2026, 4:01 PM
Flagship's UK investment marks another sign of turning tides for the UK life sciences sector, following prior big pharma funding pullouts.
PharmaShots
Nov 16, 2026, 11:49 AM
Shots: Seawolf Therapeutics has emerged from stealth with $100M, comprising a seed round led by Versant Ventures & a Series A from Versant, MPM BioImpact & Novartis Venture Fund, with participation from Eli Lilly, CRISPR Therapeutics, Alexandria Venture Investments, Pathway to Cures & others Seawolf also entered into a multi-target research collaboration & exclusive license… The post Seawolf Therapeutics Debuts with $100M and Enters into an Up to $1.2B Collaboration with Sanofi to Develop DNA Medicines appeared first on PharmaShots.
News
Google News
Nov 16, 2026, 11:15 PM
Study Finds Drug Repurposing Widely Endorsed for Rare Diseases Despite Commercial Hurdles Bioengineer.org
Google News
Nov 16, 2026, 10:33 PM
Venture firm Flagship bets £100 million to build AI-driven drug companies in Britain Reuters
Google News
Nov 16, 2026, 10:33 PM
Venture firm Flagship bets £100 million to build AI-driven drug companies in Britain CNA
Google News
Nov 16, 2026, 10:27 PM
LEO Pharma owners see market conditions as unsuitable for IPO, CEO says Reuters
Google News
Nov 16, 2026, 8:37 PM
Trust during turbulence – how does the pharmaceutical industry respond to the challenge of misinformation? The Association of the British Pharmaceutical Industry
Google News
Nov 16, 2026, 7:53 PM
Mankind licenses Lung cancer drug ensartinib from China’s Betta Pharmaceuticals pharma.economictimes.indiatimes.com
Google News
Nov 16, 2026, 7:16 PM
Venture firm Flagship bets £100 million to build AI-driven drug companies in Britain TradingView
Google News
Nov 16, 2026, 6:51 PM
Sofinnova Partners backs European life sciences sector with €725M raise Pharmaceutical Technology
Google News
Nov 16, 2026, 6:21 PM
Expert warns of battleground over global access to newer GLP-1 drugs for obesity STAT
Sponsored placement

Purchase All Medicines.Get 10% Offer